MX2021012035A - Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. - Google Patents
Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos.Info
- Publication number
- MX2021012035A MX2021012035A MX2021012035A MX2021012035A MX2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A MX 2021012035 A MX2021012035 A MX 2021012035A
- Authority
- MX
- Mexico
- Prior art keywords
- causing agents
- methods
- disease
- disease causing
- phagocytosis
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 4
- 206010057249 Phagocytosis Diseases 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 230000008782 phagocytosis Effects 0.000 title abstract 3
- 230000000779 depleting effect Effects 0.000 title abstract 2
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000001185 bone marrow Anatomy 0.000 abstract 1
- 108010025838 dectin 1 Proteins 0.000 abstract 1
- 230000002399 phagocytotic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1018—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente descripción se refiere a un método para agotar o reducir los números de agentes que provocan enfermedades, incluidas células hospedadoras, o productos de células hospedadoras, microbios o sus productos en un sujeto humano tras la administración de una molécula que provoca fagocitosis dirigida y comprende un dominio de unión que se une un receptor fagocitótico específico, tal como Dectina-1, y un dominio de unión que se une a un agente específico que provoca enfermedad. En una modalidad específica, un método de la descripción agota o reduce en tejidos, sangre o médula ósea el número de agentes que provocan enfermedades mediante fagocitosis dirigida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962830139P | 2019-04-05 | 2019-04-05 | |
PCT/US2020/026721 WO2020206354A1 (en) | 2019-04-05 | 2020-04-03 | Methods of depleting disease causing agents via antibody targeted phagocytosis |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012035A true MX2021012035A (es) | 2022-03-11 |
Family
ID=72667025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012035A MX2021012035A (es) | 2019-04-05 | 2020-04-03 | Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220169737A1 (es) |
EP (1) | EP3947467A4 (es) |
JP (1) | JP2022527646A (es) |
KR (1) | KR20220031995A (es) |
CN (1) | CN114502585A (es) |
AU (1) | AU2020253621A1 (es) |
BR (1) | BR112021019950A2 (es) |
CA (1) | CA3136272A1 (es) |
IL (1) | IL286967A (es) |
MX (1) | MX2021012035A (es) |
SG (1) | SG11202110663UA (es) |
WO (1) | WO2020206354A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20230149857A (ko) | 2016-07-07 | 2023-10-27 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
KR20230005907A (ko) | 2020-05-01 | 2023-01-10 | 볼트 바이오테라퓨틱스 인코퍼레이티드 | 항-dectin-2 항체 |
IL301956A (en) | 2020-10-07 | 2023-06-01 | Dren Bio Inc | Antibodies against dectin-1 and methods of using them |
WO2023196785A1 (en) * | 2022-04-04 | 2023-10-12 | Dren Bio, Inc. | Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof |
WO2023196786A1 (en) * | 2022-04-04 | 2023-10-12 | Dren Bio, Inc. | Anti-dectin-1 antibodies and methods of use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2688591A4 (en) * | 2011-03-22 | 2014-10-01 | Baylor Res Inst | TARGETING DENDRITIC CELLS FOR A TUBERCULOSIS VACCINE |
US20200048371A1 (en) * | 2017-03-31 | 2020-02-13 | Zymeworks Inc. | Tumor antigen presentation inducer constructs and uses thereof |
TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
EP3824076A1 (en) * | 2018-07-19 | 2021-05-26 | Oncohost Ltd | Il-31 improves efficacy of macrophage-based adoptive cell therapy for cancer |
-
2020
- 2020-04-03 MX MX2021012035A patent/MX2021012035A/es unknown
- 2020-04-03 JP JP2021560416A patent/JP2022527646A/ja active Pending
- 2020-04-03 CA CA3136272A patent/CA3136272A1/en active Pending
- 2020-04-03 AU AU2020253621A patent/AU2020253621A1/en active Pending
- 2020-04-03 SG SG11202110663UA patent/SG11202110663UA/en unknown
- 2020-04-03 KR KR1020217036237A patent/KR20220031995A/ko unknown
- 2020-04-03 CN CN202080038435.9A patent/CN114502585A/zh active Pending
- 2020-04-03 BR BR112021019950A patent/BR112021019950A2/pt unknown
- 2020-04-03 EP EP20784394.7A patent/EP3947467A4/en active Pending
- 2020-04-03 US US17/601,359 patent/US20220169737A1/en active Pending
- 2020-04-03 WO PCT/US2020/026721 patent/WO2020206354A1/en unknown
-
2021
- 2021-10-04 IL IL286967A patent/IL286967A/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021019950A2 (pt) | 2021-12-07 |
EP3947467A1 (en) | 2022-02-09 |
WO2020206354A1 (en) | 2020-10-08 |
CA3136272A1 (en) | 2020-10-08 |
JP2022527646A (ja) | 2022-06-02 |
CN114502585A (zh) | 2022-05-13 |
AU2020253621A1 (en) | 2021-11-11 |
US20220169737A1 (en) | 2022-06-02 |
KR20220031995A (ko) | 2022-03-15 |
SG11202110663UA (en) | 2021-10-28 |
EP3947467A4 (en) | 2023-01-04 |
IL286967A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012035A (es) | Metodos para agotar agentes que provocan enfermedades a traves de fagocitosis dirigida de anticuerpos. | |
EP4276114A3 (en) | Cd20 binding single domain antibodies | |
PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
UA94899C2 (ru) | Фиксированное дозирование антител к her | |
WO2020056198A3 (en) | Substituted benzazepine compounds, conjugates, and uses thereof | |
Slade Shantz et al. | Sutures versus staples for wound closure in orthopaedic surgery: a pilot randomized controlled trial | |
NZ737726A (en) | Multispecific antigen-binding molecules and uses thereof | |
SI2780368T1 (en) | INGREDIENTS AND PROCEDURES FOR INCREASING PURE MASS AND MICROWAVE WITH SPECIFIC ANTAGONISING OF GDF8 AND / OR ACTIVITY A | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
PH12015500297A1 (en) | Adoptosis-inducing agents for the treatment of cancer and immune and automoimmune disease | |
EA201100239A1 (ru) | Композиции, одновалетные в отношении связывания cd28, и способы их применения | |
CR20220521A (es) | Anticuerpos | |
AU2006342119A8 (en) | Soluble human M-CSF receptor and uses thereof | |
MX2021005085A (es) | Formulacion de anticuerpo. | |
EA202092136A1 (ru) | Способы лечения рака с помощью комбинации антитела к pd-1 и конъюгата антитела к тканевому фактору и лекарственного средства | |
WO2014110353A8 (en) | Notch ligand bound biocompatible substrates and their use in bone formation | |
WO2022031964A3 (en) | Ifngr1 binding molecules and methods of use | |
ATE360442T1 (de) | Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen | |
ZA201907371B (en) | Methods and compositions for treating allergic ocular diseases | |
EA202090741A1 (ru) | Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака | |
Bedard et al. | Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment | |
Talpur et al. | A single-center experience with brentuximab vedotin in gamma delta T-cell lymphoma | |
MX2022005904A (es) | Composiciones y metodos para la activacion de integrinas. | |
Kim et al. | Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma | |
MX2010009640A (es) | Uso de conjugados de interleucina-1 en el tratamiento de diabetes. |